Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease

Molecular Cancer

Volumn 13, Issue 1, 2014, Pages

  Shaw, Victoria E ^a   Lane, Brian ^a   Jenkinson, Claire ^a   Cox, Trevor ^a   Greenhalf, William ^a   Halloran, Christopher M ^a   Tang, Joseph ^a   Sutton, Robert ^a   Neoptolemos, John P ^a   Costello, Eithne ^a  

^a ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Biomarker; CA19 9; Cytokine; IL 8 and PDGF; IP 10; Pancreatic cancer

Indexed keywords

CA 19-9 ANTIGEN; CYTOKINE; EOTAXIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; PLATELET DERIVED GROWTH FACTOR; TUMOR MARKER; BIOLOGICAL MARKER; CARBOHYDRATE ANTIGEN 199, HUMAN; PLATELET-DERIVED GROWTH FACTOR A; TUMOR ANTIGEN;

ADULT; AGED; ARTICLE; BENIGN TUMOR; CANCER CLASSIFICATION; CHOLESTASIS; CHRONIC PANCREATITIS; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOCARCINOMA; PANCREAS DISEASE; BLOOD; CARCINOMA, PANCREATIC DUCTAL; CASE CONTROL STUDY; GENE EXPRESSION; GENETICS; METABOLISM; MIDDLE AGED; PANCREAS; PANCREATIC NEOPLASMS; PANCREATITIS, CHRONIC; PATHOLOGY; STATISTICAL MODEL;

ADULT; AGED; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; BIOMARKERS; CARCINOMA, PANCREATIC DUCTAL; CASE-CONTROL STUDIES; CHOLESTASIS; CYTOKINES; DIAGNOSIS, DIFFERENTIAL; FEMALE; GENE EXPRESSION; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PANCREAS; PANCREATIC NEOPLASMS; PANCREATITIS, CHRONIC; PLATELET-DERIVED GROWTH FACTOR;

EID: 84901496167     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-13-114     Document Type: Article

References (47)

1. Costello E, Greenhalf W, Neoptolemos JP. New biomarkers and targets in pancreatic cancer and their application to treatment. Nat Rev Gastroenterol Hepatol 2012, 9:435-444. 10.1038/nrgastro.2012.119, 22733351.
2. Costello E, Neoptolemos JP. Pancreatic cancer in 2010: new insights for early intervention and detection. Nat Rev Gastroenterol Hepatol 2011, 8:71-73. 10.1038/nrgastro.2010.214, 21293504.
3. Martin KJ, Fournier MV, Reddy GP, Pardee AB. A need for basic research on fluid-based early detection biomarkers. Cancer Res 2010, 70:5203-5206. 10.1158/0008-5472.CAN-10-0987, 20587531.
4. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, Somerfield MR, Hayes DF, Bast RC. Asco: ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006, 24:5313-5327. 10.1200/JCO.2006.08.2644, 17060676.
5. Wong D, Ko AH, Hwang J, Venook AP, Bergsland EK, Tempero MA. Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy. Pancreas 2008, 37:269-274. 10.1097/MPA.0b013e31816d8185, 18815548.
6. Winter JM, Yeo CJ, Brody JR. Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer. J Surg Oncol 2013, 107:15-22. 10.1002/jso.23192, 22729569.
7. Sener SF, Fremgen A, Menck HR, Winchester DP. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National cancer database. J Am Coll Surg 1999, 189:1-7. 10.1016/S1072-7515(99)00075-7, 10401733.
8. Singh S, Tang SJ, Sreenarasimhaiah J, Lara LF, Siddiqui A. The clinical utility and limitations of serum carbohydrate antigen (CA19-9) as a diagnostic tool for pancreatic cancer and cholangiocarcinoma. Dig Dis Sci 2011, 56:2491-2496. 10.1007/s10620-011-1709-8, 21516323.
9. Hamada S, Shimosegawa T. Biomarkers of pancreatic cancer. Pancreatology 2011, 11(Suppl 2):14-19.
10. Smith RA, Bosonnet L, Ghaneh P, Raraty M, Sutton R, Campbell F, Neoptolemos JP. Preoperative CA19-9 levels and lymph node ratio are independent predictors of survival in patients with resected pancreatic ductal adenocarcinoma. Dig Surg 2008, 25:226-232. 10.1159/000140961, 18577869.
11. von Ritter C, Eder MI, Stieber P, Lamerz R, Jungst D, Strigl M, Meyer G, Reuter C, Paumgartner G. Biliary mucin secreted by cultured human gallbladder epithelial cells carries the epitope of CA 19-9. Anticancer Res 1997, 17:2931-2934.
12. Wingren C, Sandstrom A, Segersvard R, Carlsson A, Andersson R, Lohr M, Borrebaeck CA. Identification of serum biomarker signatures associated with pancreatic cancer. Cancer Res 2012, 72:2481-2490. 10.1158/0008-5472.CAN-11-2883, 22589272.
13. Park HD, Kang ES, Kim JW, Lee KT, Lee KH, Park YS, Park JO, Lee J, Heo JS, Choi SH, Choi DW, Kim S, Lee JK, Lee SY. Serum CA19-9, cathepsin D, and matrix metalloproteinase-7 as a diagnostic panel for pancreatic ductal adenocarcinoma. Proteomics 2012, 12:3590-3597. 10.1002/pmic.201200101, 23065739.
14. Faca VM, Song KS, Wang H, Zhang Q, Krasnoselsky AL, Newcomb LF, Plentz RR, Gurumurthy S, Redston MS, Pitteri SJ, Pereira-Faca SR, Ireton RC, Katayama H, Glukhova V, Phanstiel D, Brenner DE, Anderson MA, Misek D, Scholler N, Urban ND, Barnett MJ, Edelstein C, Goodman GE, Thornquist MD, McIntosh MW, DePinho RA, Bardeesy N, Hanash SM. A mouse to human search for plasma proteome changes associated with pancreatic tumor development. PLoS Med 2008, 5:e123. 10.1371/journal.pmed.0050123, 2504036, 18547137.
15. Brand RE, Nolen BM, Zeh HJ, Allen PJ, Eloubeidi MA, Goldberg M, Elton E, Arnoletti JP, Christein JD, Vickers SM, Langmead CJ, Landsittel DP, Whitcomb DC, Grizzle WE, Lokshin AE. Serum biomarker panels for the detection of pancreatic cancer. Clin Cancer Res 2011, 17:805-816. 10.1158/1078-0432.CCR-10-0248, 3075824, 21325298.
16. Pan S, Chen R, Crispin DA, May D, Stevens T, McIntosh MW, Bronner MP, Ziogas A, Anton-Culver H, Brentnall TA. Protein alterations associated with pancreatic cancer and chronic pancreatitis found in human plasma using global quantitative proteomics profiling. J Proteome Res 2011, 10:2359-2376. 10.1021/pr101148r, 3090497, 21443201.
17. Bauer AS, Keller A, Costello E, Greenhalf W, Bier M, Borries A, Beier M, Neoptolemos J, Buchler M, Werner J, Giese N, Hoheisel JD. Diagnosis of pancreatic ductal adenocarcinoma and chronic pancreatitis by measurement of microRNA abundance in blood and tissue. PLoS One 2012, 7:e34151. 10.1371/journal.pone.0034151, 3325244, 22511932.
18. Tonack S, Aspinall-O'Dea M, Neoptolemos JP, Costello E. Pancreatic cancer: proteomic approaches to a challenging disease. Pancreatology 2009, 9:567-576. 10.1159/000212083, 19657212.
19. Blanchet X, Langer M, Weber C, Koenen RR, von Hundelshausen P. Touch of chemokines. Front Immunol 2012, 3:175. 3394994, 22807925.
20. Evans A, Costello E. The role of inflammatory cells in fostering pancreatic cancer cell growth and invasion. Front Physiol 2012, 3:270. 3431795, 22969725.
21. Schetter AJ, Heegaard NH, Harris CC. Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis 2010, 31:37-49. 10.1093/carcin/bgp272, 2802675, 19955394.
22. Dudoit S, Fridlyand J, Speed TP. Comparison of discrimination methods for the classification of tumors using gene expression data. J Am Stat Assoc 2002, 97:77-87.
23. Joergensen MT, Brunner N, De Muckadell OB. Comparison of circulating MMP-9, TIMP-1 and CA19-9 in the detection of pancreatic cancer. Anticancer Res 2010, 30:587-592.
24. Xue A, Scarlett CJ, Chung L, Butturini G, Scarpa A, Gandy R, Wilson SR, Baxter RC, Smith RC. Discovery of serum biomarkers for pancreatic adenocarcinoma using proteomic analysis. Br J Cancer 2010, 103:391-400. 10.1038/sj.bjc.6605764, 2920018, 20588270.
25. Ebrahimi B, Tucker SL, Li D, Abbruzzese JL, Kurzrock R. Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis. Cancer 2004, 101:2727-2736. 10.1002/cncr.20672, 15526319.
26. Yan L, Tonack S, Smith R, Dodd S, Jenkins RE, Kitteringham N, Greenhalf W, Ghaneh P, Neoptolemos JP, Costello E. Confounding effect of obstructive jaundice in the interpretation of proteomic plasma profiling data for pancreatic cancer. J Proteome Res 2009, 8:142-148. 10.1021/pr800451h, 19055369.
27. Tonack S, Jenkinson C, Cox T, Elliott V, Jenkins RE, Kitteringham NR, Greenhalf W, Shaw V, Michalski CW, Friess H, Neoptolemos JP, Costello E. iTRAQ reveals candidate pancreatic cancer serum biomarkers: influence of obstructive jaundice on their performance. Br J Cancer 2013, 108:1846-1853. 10.1038/bjc.2013.150, 3658525, 23579209.
28. Chen Y, Shi M, Yu GZ, Qin XR, Jin G, Chen P, Zhu MH. Interleukin-8, a promising predictor for prognosis of pancreatic cancer. World J Gastroenterol 2012, 18:1123-1129. 10.3748/wjg.v18.i10.1123, 3296988, 22416189.
29. Xie K. Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev 2001, 12:375-391. 10.1016/S1359-6101(01)00016-8, 11544106.
30. Hussain F, Wang J, Ahmed R, Guest SK, Lam EW, Stamp G, El-Bahrawy M. The expression of IL-8 and IL-8 receptors in pancreatic adenocarcinomas and pancreatic neuroendocrine tumours. Cytokine 2010, 49:134-140. 10.1016/j.cyto.2009.11.010, 20005738.
31. Dima SO, Tanase C, Albulescu R, Herlea V, Chivu-Economescu M, Purnichescu-Purtan R, Dumitrascu T, Duda DG, Popescu I. An exploratory study of inflammatory cytokines as prognostic biomarkers in patients with ductal pancreatic adenocarcinoma. Pancreas 2012, 41:1001-1007. 10.1097/MPA.0b013e3182546e13, 22722257.
32. Bellone G, Novarino A, Chiappino I, Gramigni C, Carbone A, Addeo A, Tonel E, Bertetto O, Emanuelli G. Circulating vascular endothelial growth factor and interferon-gamma-inducible protein-10 levels in pancreatic cancer during chemotherapy. Anticancer Res 2005, 25:3287-3291.
33. Toiyama Y, Fujikawa H, Kawamura M, Matsushita K, Saigusa S, Tanaka K, Inoue Y, Uchida K, Mohri Y, Kusunoki M. Evaluation of CXCL10 as a novel serum marker for predicting liver metastasis and prognosis in colorectal cancer. Int J Oncol 2012, 40:560-566.
34. Liu M, Guo S, Stiles JK. The emerging role of CXCL10 in cancer (Review). Oncol Lett 2011, 2:583-589. 3406435, 22848232.
35. Mei K, Wang L, Tian L, Yu J, Zhang Z, Wei Y. Antitumor efficacy of combination of interferon-gamma-inducible protein 10 gene with gemcitabine, a study in murine model. J Exp Clin Cancer Res 2008, 27:63. 10.1186/1756-9966-27-63, 2586014, 18983688.
36. Yang X, Chu Y, Wang Y, Zhang R, Xiong S. Targeted in vivo expression of IFN-gamma-inducible protein 10 induces specific antitumor activity. J Leukoc Biol 2006, 80:1434-1444. 10.1189/jlb.0306212, 16980511.
37. Barber MD, Fearon KC, Ross JA. Relationship of serum levels of interleukin-6, soluble interleukin-6 receptor and tumour necrosis factor receptors to the acute-phase protein response in advanced pancreatic cancer. Clin Sci (Lond) 1999, 96:83-87. 10.1042/CS19980185, 9857110.
38. Bartsch R, Woehrer S, Raderer M, Hejna M. Serum interleukin-6 levels in patients with gastric MALT lymphoma compared to gastric and pancreatic cancer. Anticancer Res 2006, 26:3187-3190.
39. Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol 2013, 14:e218-228. 10.1016/S1470-2045(12)70582-X, 23639322.
40. Zeh HJ, Winikoff S, Landsittel DP, Gorelik E, Marrangoni AM, Velikokhatnaya L, Winans MT, Lee K, Moser A, Bartlett D, Lotze MT, Siegfried JM, Whitcomb D, Papacristou G, Slivka A, Bigbee WL, Lokshin AE. Multianalyte profiling of serum cytokines for detection of pancreatic cancer. Cancer Biomark 2005, 1:259-269.
41. Chowdhury F, Williams A, Johnson P. Validation and comparison of two multiplex technologies, Luminex and Mesoscale Discovery, for human cytokine profiling. J Immunol Methods 2009, 340:55-64. 10.1016/j.jim.2008.10.002, 18983846.
42. Varadhachary GR, Tamm EP, Abbruzzese JL, Xiong HQ, Crane CH, Wang H, Lee JE, Pisters PW, Evans DB, Wolff RA. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol 2006, 13:1035-1046. 10.1245/ASO.2006.08.011, 16865597.
43. Choti MA, Dixon E, Tyler D. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement by Callery et al. Ann Surg Oncol 2009, 16:1734-1735. 10.1245/s10434-009-0411-y, 19390901.
44. Callery MP, Chang KJ, Fishman EK, Talamonti MS, William Traverso L, Linehan DC. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol 2009, 16:1727-1733. 10.1245/s10434-009-0408-6, 19396496.
45. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, Muller M. pROC: an open-source package for R and S + to analyze and compare ROC curves. BMC Bioinforma 2011, 12:77.
46. Sing T, Sander O, Beerenwinkel N, Lengauer T. ROCR: visualizing classifier performance in R. Bioinformatics 2005, 21:3940-3941. 10.1093/bioinformatics/bti623, 16096348.
47. Hothorn T, Leisch F, Zeileis A, Hornik K. The design and analysis of benchmark experiments. J Comput Graph Stat 2005, 14:675-699.